Safety Assessment Committee (SAC) Chair Consultant

Safety Assessment committee (SAC) Chair consultant

Fully remote

Mapp Biopharmaceutical, Inc. (Mapp) develops novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefence. Mapp is developing monoclonal antibodies for the treatment of filoviruses and is seeking an external consultant (1099) to serve as Chair for its Safety Assessment Committee (SAC). The SAC Chair should possess an MD or PhD with extensive pharmaceutical/pharmacovigilance experience required, and with monoclonal antibody and/ or in infectious diseases experience preferred.

The Safety Assessment Committee will convene on a quarterly basis (for approximately 1-2 hours), with ad hoc meetings scheduled, as needed. The Consultant will be responsible for reviewing available clinical and non-clinical safety data related to one of Mapp's products. This will include an independent review of historical information as well as new safety information as it is generated. The Consultant will attend and lead the committee discussion virtually for all SAC meetings, as well as review and approve meeting minutes.

The goal of Mapp's pharmacovigilance program, and the SAC specifically, is to ensure that the safety profile of its product is characterized, monitored and reported over the course of development to ensure the safety of all participants and patients who may receive Mapp's products.

As an independent consultant, the SAC Chair must carry their own errors & omissions insurance. Mapp invites you to contact us expressing your interest in this consulting role by sending an email with your qualifications to: clinical.ops@mappbio.com.